Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genomic Research Center, |
RCV000087150 | SCV000746314 | likely pathogenic | Martsolf syndrome | 2017-12-03 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000850507 | SCV000992710 | pathogenic | Martsolf syndrome; Warburg micro syndrome 2 | 2018-10-12 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000850507 | SCV002265556 | pathogenic | Martsolf syndrome; Warburg micro syndrome 2 | 2024-01-26 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 426 of the RAB3GAP2 protein (p.Arg426Cys). This variant is present in population databases (rs587777167, gnomAD 0.009%). This missense change has been observed in individual(s) with clinical features of Martsolf syndrome (PMID: 23420520; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 100787). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RAB3GAP2 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects RAB3GAP2 function (PMID: 24891604). For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV001807041 | SCV000120012 | pathogenic | Martsolf syndrome 1 | 2013-05-01 | no assertion criteria provided | literature only | |
Gene |
RCV000087150 | SCV000778360 | not provided | Martsolf syndrome | no assertion provided | literature only |